Buy Protonix through the unique service that maximize your savings

Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company,
today reported financial and operating results for the quarter and
year ended December 31, 2007.

Key financial results for the 2007 fourth quarter:

— Total revenues of $28.3 million increased 38% compared with
$20.5 million in the prior year period

— Net product sales of $24.1 million increased 24% compared with
$19.3 million in the prior year period

— Net loss of $8.0 million, or $0.16 per share, versus a net
loss of $7.5 million, or $0.15 per share, in the prior year
period

Key financial results for the 2007 full year:

— Total revenues of $94.4 million for the year ended December
31, 2007 increased 92% compared with total revenues of $49.2
million for the year ended December 31, 2006

— Net product sales of $79.4 million increased 73% compared with
net product sales of $46.0 million in the prior year

— Net loss for the year ended December 31, 2007 of $44.3
million, or $0.87 per share, versus a net loss of $56.5
million, or $1.19 per share, for the year ended December 31,
2006

“Santarus achieved several significant accomplishments in 2007. We
nearly doubled revenues, launched two co-promotion products, announced
progress with Schering-Plough’s ZEGERID(R) brand OTC product
development, signed license and distribution agreements for
immediate-release omeprazole products with GlaxoSmithKline in more
than 100 countries and reduced our net loss by 22%,” said Gerald T.
Proehl, president and chief executive officer of Santarus. “In
addition, contributions from our business development agreements
allowed us to fund our operating cash needs without issuing dilutive
equity capital.”

Additional Business Highlights

Key fourth quarter accomplishments and recent highlights include:

— Grew ZEGERID (omeprazole/sodium bicarbonate) brand total
prescriptions to approximately 253,000 in the fourth quarter
of 2007, an increase of 71% versus total prescriptions in the
fourth quarter of 2006. For the full 2007 year, total ZEGERID
prescriptions grew approximately 116% compared with total
ZEGERID prescriptions in 2006.

— Received an $11.5 million upfront payment in December 2007
under agreements granting exclusive rights to GlaxoSmithKline
plc (GSK) to commercialize prescription and over-the-counter
(OTC) immediate-release omeprazole products for a number of
markets in GSK’s International Region (including in Africa,
Asia, the Middle-East, and Central and South America) and to
distribute and sell ZEGERID brand prescription products in
Puerto Rico and the U.S. Virgin Islands. According to the
market research firm IMS Health Incorporated, aggregate annual
retail sales for proton pump inhibitor (PPI) products in
selected markets covered by these agreements are approximately
$2 billion.

— Announced the launch of ZEGERID Capsules and Powder for Oral
Suspension by GSK in Puerto Rico and the U.S. Virgin Islands
in February 2008. The total annual retail sales of all
prescription PPI products in Puerto Rico and the U.S. Virgin
Islands are approximately $124 million, according to IMS
Health.

— Reported positive results in early January 2008 from a
clinical trial with immediate-release ZEGERID Capsules 40
mg/1100 mg and two leading PPIs, Protonix(R) (pantoprazole
sodium) delayed-release tablets 40 mg and Prevacid(R)
(lansoprazole) delayed-release capsules 30 mg. The study
evaluated the effect of morning PPI dosing on 24-hour gast